LIVIVO - Search results -

Search results

Result 1 - 10 of total 60

Search options

Article ; Online: Mycoplasma genitalium: A descriptive study of 196 cases.

Alamon-Reig, Francesc / Riera-Monroig, Josep / González-Cordón, Ana / Bosch, Jordi / Alsina, Mercè / Fuertes, Irene

Indian journal of dermatology, venereology and leprology

2022 Volume 88, Issue 6, Page(s) 873

MeSH term(s)	Humans ; Mycoplasma genitalium ; Urethritis ; Mycoplasma Infections/complications ; Mycoplasma Infections/diagnosis ; Mycoplasma Infections/epidemiology ; Prevalence
Language	English
Publishing date	2022-08-12
Publishing country	United States
Document type	Journal Article
ZDB-ID	416068-x
ISSN	0973-3922 ; 0019-5162 ; 0378-6323
ISSN (online)	0973-3922
ISSN	0019-5162 ; 0378-6323
DOI	10.25259/IJDVL_217_2021
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 85: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Major cardiovascular events after COVID-19 in people with HIV.

Martín-Iguacel, Raquel / Moreno-Fornés, Sergio / Bruguera, Andreu / Aceitón, Jordi / Nomah, Daniel Kwakye / González-Cordón, Ana / Domingo, Pere / Curran, Adrian / Imaz, Arkaitz / Juanola, David Dalmau / Peraire, Joaquim / Borjabad, Beatriz / Fernandez, Laia Arbones / Johansen, Isik Somuncu / Miró, José M / Casabona, Jordi / Llibre, Josep M

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

2024 Volume 30, Issue 5, Page(s) 674–681

Abstract: Objectives: To assess the effect of COVID-19 on the postacute risk of cardiovascular events (CVEs) among people with HIV (PWH).: Methods: Population-based matched cohort, including all PWH ≥16 years in the Catalan PISCIS HIV cohort. We estimated the ... ...

Abstract	Objectives: To assess the effect of COVID-19 on the postacute risk of cardiovascular events (CVEs) among people with HIV (PWH). Methods: Population-based matched cohort, including all PWH ≥16 years in the Catalan PISCIS HIV cohort. We estimated the incidence rate of the first CVE after COVID-19, analysed it a composite outcome (2020-2022). We adjusted for baseline differences using inverse probability weighting and used competing risk analysis. Results: We included 4199 PWH with and 14 004 PWH without COVID-19. The median follow-up was 243 days (interquartile range [IQR]: 93-455), 82% (14 941/18 203) were men, with a median age of 47 years. Overall, 211 PWH with COVID-19 and 621 without developed CVE, with an incidence rate of 70.2 and 56.8/1000 person-years, respectively. During COVID-19 infection, 7.6% (320/4199) required hospitalization and 0.6% (25/4199) intensive care unit admission, 97% (4079/4199) had CD4 Discussion: COVID-19 was associated with a 30% increased risk of major CVE in PWH during the subsequent year, suggesting that COVID-19 should be considered an additional CVD risk in PWH in the short term.
MeSH term(s)	Humans ; COVID-19/epidemiology ; COVID-19/complications ; Male ; HIV Infections/complications ; HIV Infections/epidemiology ; Middle Aged ; Cardiovascular Diseases/epidemiology ; Female ; Adult ; Incidence ; SARS-CoV-2 ; Risk Factors ; Cohort Studies ; Spain/epidemiology ; Hospitalization/statistics & numerical data ; CD4 Lymphocyte Count
Language	English
Publishing date	2024-02-09
Publishing country	England
Document type	Journal Article
ZDB-ID	1328418-6
ISSN	1469-0691 ; 1470-9465 ; 1198-743X
ISSN (online)	1469-0691
ISSN	1470-9465 ; 1198-743X
DOI	10.1016/j.cmi.2024.02.006
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4541: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 284: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Toxic-Induced Encephalopathy Following Chemsex in a Young HIV-Positive Male: A Complex Case of Acute Cognitive Impairment with Anterograde Amnesia and Behavioral Alterations.

Inciarte, Alexy / de la Mora, Lorena / Huaier-Arriazu, Emilio / Torres, Berta / Cañizares, Silvia / Zamora, Elizabeth / Laguno, Montserrat / Gonzalez-Cordón, Ana / Foncillas, Alberto / Chivite, Ivan / Calvo, Júlia / Ambrosioni, Juan / Martínez, Esteban / Blanco, Jose Luis / Miro, J M / Martinez-Rebollar, Maria / Mallolas, Josep

Infectious diseases and therapy

2024 Volume 13, Issue 4, Page(s) 647–658

Abstract: Background: A broadened clinical spectrum of concomitant complications emerges among the escalating incidence of substance use, particularly within the 'chemsex' context. This case exemplifies the profound neurotoxic repercussions and neurological risk ... ...

Abstract	Background: A broadened clinical spectrum of concomitant complications emerges among the escalating incidence of substance use, particularly within the 'chemsex' context. This case exemplifies the profound neurotoxic repercussions and neurological risk of chemsex in a young HIV-positive male and addresses the multifaceted challenges of such evolving paradigms in substance utilization. Clinical finding: After consuming cannabis, poppers, methamphetamine, and cocaine, a 28-year-old HIV-positive male exhibited significant neurological and cognitive impairment. The initial presentation included dysarthria and profound anterograde amnesia. Laboratory findings showed leukocytosis with a PCR of 3 mg/dl - elevated cerebrospinal fluid protein levels with no cells. Urine toxicology returned positive for cannabis and amphetamines. A brain CT scan revealed bilateral and symmetrical hippocampi and pale globes hypodensity, indicative of toxic-metabolic encephalopathy. MRI further identified lesions in the globus pallidus, cerebellum, and hippocampi. Following the detection of toxic encephalopathy, Initial neuropsychological was performed screening using the Montreal Cognitive Assessment (MoCA), which highlighted immediate memory deficits. An in-depth neuropsychological assessment conducted 3 weeks later included the Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV), the Rey Auditory Verbal Learning Test (RAVLT), and tests for visuospatial skills, motor functions, and memory recall. The evaluations revealed pronounced anterograde amnesia, persistent long-term memory inconsistencies, and notable executive function challenges, detailed in Table 1. Conclusions: The detailed analysis of this case underpins the severe neurological consequences that can manifest from heavy substance use. Comprehensive diagnostic evaluations, including neuroimaging and neuropsychological assessments, are crucial in elucidating the full spectrum of substance-induced cognitive impairments. There is an urgent need for enhanced public awareness and preventative measures, especially in the context of chemsex, to bring forth multifaceted health, social, and government implications that modern society must adeptly navigate.
Language	English
Publishing date	2024-04-03
Publishing country	New Zealand
Document type	Journal Article
ZDB-ID	2701611-0
ISSN	2193-6382 ; 2193-8229
ISSN (online)	2193-6382
ISSN	2193-8229
DOI	10.1007/s40121-024-00962-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: About "Executive summary of the GeSIDA consensus document on control and monitoring of HIV-infected patients".

Modesto Dos Santos, Joao Luis / Laguno, Montserrat / Inciarte, Alexy / González-Cordón, Ana

Enfermedades infecciosas y microbiologia clinica (English ed.)

2020 Volume 38, Issue 6, Page(s) 299–300

MeSH term(s)	Anti-HIV Agents/therapeutic use ; Antiretroviral Therapy, Highly Active ; Consensus ; HIV Infections/drug therapy ; Humans
Chemical Substances	Anti-HIV Agents
Language	Spanish
Publishing date	2020-01-10
Document type	Letter ; Comment
ISSN	2529-993X
ISSN (online)	2529-993X
DOI	10.1016/j.eimc.2019.12.006
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.

González-Cordón, Ana / Assoumou, Lambert / Moyle, Graeme / Waters, Laura / Johnson, Margaret / Domingo, Pere / Fox, Julie / Stellbrink, Hans-Jürgen / Guaraldi, Giovanni / Masiá, Mar / Gompels, Mark / De Wit, Stephane / Florence, Eric / Esser, Stefan / Raffi, François / Behrens, Georg / Pozniak, Anton / Gatell, Jose M / Martínez, Esteban

The Journal of antimicrobial chemotherapy

2023 Volume 78, Issue 9, Page(s) 2361–2365

Abstract: Background: In the NEAT022 trial, switching from boosted PIs (PI/r) to dolutegravir in people with HIV (PWH) with high cardiovascular risk decreased plasma lipids, soluble CD14 and adiponectin, and showed consistent favourable, although non-significant, ...

Abstract	Background: In the NEAT022 trial, switching from boosted PIs (PI/r) to dolutegravir in people with HIV (PWH) with high cardiovascular risk decreased plasma lipids, soluble CD14 and adiponectin, and showed consistent favourable, although non-significant, effects on carotid intima-media thickness (CIMT) progression at 48 weeks. We hereby communicate planned final 96 week results on biomarker changes and CIMT progression. Methods: PWH on a PI/r-based triple therapy regimen were randomly assigned (1:1) to switch the PI/r component to dolutegravir either immediately (DTG-I group) or after 48 weeks (DTG-D group) and were followed up to 96 weeks. We assessed changes in biomarkers associated with inflammation, endothelial dysfunction, monocyte immune activation, oxidation, insulin resistance, hypercoagulability, heart failure, myocardial injury and glomerular and tubular kidney injury, and right and left CIMT progression at 48 and 96 weeks. Results: Of 415 PWH randomized, 287 (69%) and 143 (34%) contributed to the biomarker and CIMT substudies respectively. There were significant 96 week changes in biomarkers associated with inflammation, immune activation, oxidation, insulin resistance and myocardial injury. Most changes were favourable, except for adiponectin reduction, which may suggest higher insulin resistance. We were unable to detect significant changes in the progression of CIMT between arms or within arms at 96 weeks. Discussion: After 96 weeks, switching from PI/r to dolutegravir in PWH with high cardiovascular risk led to significant changes in several biomarkers associated with cardiovascular disease. Although most changes were favourable, adiponectin reduction was not. There were non-significant changes in CIMT progression.
MeSH term(s)	Humans ; HIV Protease Inhibitors/therapeutic use ; Cardiovascular Diseases/chemically induced ; Cardiovascular Diseases/drug therapy ; HIV Infections/complications ; HIV Infections/drug therapy ; Adiponectin/therapeutic use ; Carotid Intima-Media Thickness ; Insulin Resistance ; Biomarkers ; Inflammation ; Anti-HIV Agents/therapeutic use
Chemical Substances	dolutegravir (DKO1W9H7M1) ; HIV Protease Inhibitors ; Adiponectin ; Biomarkers ; Anti-HIV Agents
Language	English
Publishing date	2023-07-24
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	191709-2
ISSN	1460-2091 ; 0305-7453
ISSN (online)	1460-2091
ISSN	0305-7453
DOI	10.1093/jac/dkad247
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1197: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 124: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Perception of quality of care using patient reported experience measures (PREMs) in a cohort of adults with HIV: A cross-sectional study.

de Lazzari, Elisa / Berrocal, Leire / Fernández, Emma / Laguno, Montserrat / Chivite, Iván / Torres, Berta / González-Cordón, Ana / de la Mora, Lorena / Ambrosioni, Juan / Iniciarte, Alexy / Blanco, José Luís / Miró, Josep Maria / Martínez, Esteban / Martínez-Rebollar, Maria / Mallolas, Josep

Medicine

2023 Volume 102, Issue 14, Page(s) e33442

Abstract: Human immunodeficiency virus (HIV) infection is considered a chronic disease. Antiretroviral therapy has allowed persons with HIV (PLWHIV) to achieve the 90-90-90 objectives proposed by the World Health Organization for 2020; but an additional challenge ... ...

Abstract	Human immunodeficiency virus (HIV) infection is considered a chronic disease. Antiretroviral therapy has allowed persons with HIV (PLWHIV) to achieve the 90-90-90 objectives proposed by the World Health Organization for 2020; but an additional challenge is getting an adequate health-related quality of life. A determining factor in the health-related quality of life of PLWHIV is the health care they perceive to receive. In this sense, we aimed to assess the perception of the outpatient care provided and to identify possible areas for improvement in a single-center, cross-sectional study at the HIV unit of Hospital Clínic, Barcelona. We sought patient reported experience measures by an anonymous e-survey with 11 statements based on a 1 to 6 Likert scale, and a final question measuring user satisfaction and loyalty through the Net Promoter Score (NPS). All PLWHIV with at least a clinical visit between January 1, 2020 and October 14, 2021 were invited. Of 5493 PLWHIV e-mailed, 1633 (30%) responded to the survey. The overall evaluation of clinical care was very favorable. The evaluation of the physical environment and facilities and the time spent in the waiting room received the lowest scores. According to the Net Promoter Score test results, 66% of respondents were willing to recommend this service, and 11% were not. Thus, monitoring patient reported experience measures in PLWHIV actively receiving outpatient care in our hospital allowed to identify the users' perception on quality of the care received, to determine the rate of satisfaction with the care, and to identify areas for improvement.
MeSH term(s)	Adult ; Humans ; Cross-Sectional Studies ; Quality of Life ; HIV Infections/drug therapy ; Perception ; Patient Reported Outcome Measures ; Patient Satisfaction
Language	English
Publishing date	2023-04-07
Publishing country	United States
Document type	Journal Article
ZDB-ID	80184-7
ISSN	1536-5964 ; 0025-7974
ISSN (online)	1536-5964
ISSN	0025-7974
DOI	10.1097/MD.0000000000033442
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.171: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Clinical use and effectiveness of dolutegravir and lamivudine: a long-term, real-world, retrospective study.

Martínez-Serra, Adrián / De Lazzari, Elisa / Berrocal, Leire / Foncillas, Alberto / De La Mora, Lorena / Inciarte, Alexy / Chivite, Iván / González-Cordón, Ana / Martínez-Rebollar, María / Torres, Berta / Laguno, Montserrat / Blanco, José Luis / Martínez, Esteban / Mallolas, Josep / Ambrosioni, Juan

The Journal of antimicrobial chemotherapy

2023 Volume 78, Issue 8, Page(s) 1955–1962

Abstract: Background: The use of dolutegravir/lamivudine is based on solid clinical trials; however, real-world data remain limited.: Objectives: To provide data on the clinical use and effectiveness of dolutegravir/lamivudine in persons with HIV in a real- ... ...

Abstract	Background: The use of dolutegravir/lamivudine is based on solid clinical trials; however, real-world data remain limited. Objectives: To provide data on the clinical use and effectiveness of dolutegravir/lamivudine in persons with HIV in a real-world scenario. Patients and methods: Retrospective, single-centre and observational study. We included all adults starting dolutegravir/lamivudine since November 2014. We reported all demographic, virological and immunological variables at baseline and assessed effectiveness [on treatment (OT), modified ITT (mITT) and ITT in those persons who reached 6 and 12 month follow-ups (M6 and M12). Results: Of the 1058 persons, 9 were treatment-naive; the final analysis included 1049 treatment-experienced people with HIV. Median (IQR) follow-up was 1 (0.3-1.6) years, with 81% and 63% persons reaching M6 and M12, respectively. The longest use of dolutegravir/lamivudine was 7.4 years. Per OT, mITT and ITT, HIV-RNA < 50 copies/mL was 97%, 92% and 81% (M6) and 98%, 90% and 80% (M12), respectively. Females [adjusted risk ratio, aRR (95% CI): 1.69 (1.19-2.40)]; immediate, previous PI-based regimen [aRR (95% CI): 1.67 (1.09-2.56)]; and viral load (VL) ≥ 50 copies/mL at dolutegravir/lamivudine initiation [aRR (95% CI): 3.36 (2.32-4.88)] were independently associated with lack of effectiveness at M12; other demographic, immunological and virological variables like previous M184V/I substitutions or virological failure, were unrelated. Of the total, 944 (90%) continued dolutegravir/lamivudine. The most frequent known reason for discontinuation was toxicity [48 (46%) cases]. Conclusions: In our real-world experience, virological suppression rates were high for treatment-experienced persons on dolutegravir/lamivudine; however, we identified subgroups with a higher risk of lack of effectiveness at M12, who may benefit from closer follow-ups.
MeSH term(s)	Adult ; Female ; Humans ; Lamivudine/therapeutic use ; Retrospective Studies ; HIV Infections/drug therapy ; Anti-HIV Agents/therapeutic use ; Drug Therapy, Combination ; Heterocyclic Compounds, 3-Ring/therapeutic use ; Oxazines/therapeutic use ; Pyridones/therapeutic use
Chemical Substances	Lamivudine (2T8Q726O95) ; dolutegravir (DKO1W9H7M1) ; Anti-HIV Agents ; Heterocyclic Compounds, 3-Ring ; Oxazines ; Pyridones
Language	English
Publishing date	2023-06-13
Publishing country	England
Document type	Observational Study ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	191709-2
ISSN	1460-2091 ; 0305-7453
ISSN (online)	1460-2091
ISSN	0305-7453
DOI	10.1093/jac/dkad189
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1197: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 124: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Sex-based epidemiological and immunovirological characteristics of people living with HIV in current follow-up at a tertiary hospital: a comparative retrospective study, Catalonia, Spain, 1982 to 2020.

Toyos, Sara / Berrocal, Leire / González-Cordón, Ana / Inciarte, Alexy / de la Mora, Lorena / Martínez-Rebollar, María / Laguno, Montserrat / Fernández, Emma / Ambrosioni, Juan / Chivite, Iván / de Lazzari, Elisa / Blanco, José Luis / Martínez, Esteban / Miró, José M / Mallolas, Josep / Torres, Berta

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

2023 Volume 28, Issue 10

Abstract: BackgroundEpidemiological and immunovirological features of people living with HIV (PLWH) can vary by sex.AimTo investigate, particularly according to sex, characteristics of PLWH who consulted a tertiary hospital in Barcelona, Spain, in 1982-2020 ... ...

Abstract	BackgroundEpidemiological and immunovirological features of people living with HIV (PLWH) can vary by sex.AimTo investigate, particularly according to sex, characteristics of PLWH who consulted a tertiary hospital in Barcelona, Spain, in 1982-2020.MethodsPLWH, still in active follow-up in 2020 were retrospectively analysed by sex, age at diagnosis, age at data extraction (December 2020), birth place, CD4+ cell counts, and virological failure.ResultsIn total, 5,377 PLWH (comprising 828 women; 15%) were included. HIV diagnoses in women appeared to decrease from the 1990s, representing 7.4% (61/828) of new diagnoses in 2015-2020. From 1997, proportions of new HIV diagnoses from patients born in Latin America seemed to increase; moreover, for women born outside of Spain, the median age at diagnosis appeared to become younger than for those born in Spain, with significant differences observed in 2005-2009 and 2010-2014 (31 vs 39 years (p = 0.001), and 32 vs 42 years (p < 0.001) respectively), but not in 2015-2020 (35 vs 42 years; p = 0.254). Among women, proportions of late diagnoses (CD4+ cells/mm3 < 350) were higher than men (significantly in 2015-2020: 62% (32/52) vs 46% (300/656); p = 0.030). Initially, virological failure rates were higher in women than men, but they were similar in 2015-2020 (12% (6/52) vs 8% (55/659); p = 0.431). Women ≥ 50 years old represented 68% (564/828) of women actively followed up in 2020.ConclusionsWomen still have higher rates of late HIV diagnoses than men. Among currently-followed-up women, ≥ 50 year-olds, who need age-adapted care represent a high percentage. Stratifying PLWH by sex matters for HIV prevention and control interventions.
MeSH term(s)	Male ; Humans ; Female ; Middle Aged ; Spain/epidemiology ; Retrospective Studies ; HIV Infections/diagnosis ; HIV Infections/drug therapy ; HIV Infections/epidemiology ; Tertiary Care Centers ; Follow-Up Studies
Language	English
Publishing date	2023-02-22
Publishing country	Sweden
Document type	Journal Article
ZDB-ID	1338803-4
ISSN	1560-7917 ; 1025-496X
ISSN (online)	1560-7917
ISSN	1025-496X
DOI	10.2807/1560-7917.ES.2023.28.10.2200317
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5066: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia: a pilot study.

Blanco, José L / Rojas, Jhon / de Lazzari, Elisa / Inciarte, Alexy / Subirana, Mar / Callau, Pilar / Martinez-Rebollar, María / Laguno, Montserrat / Mallolas, Josep / de la Mora, Lorena / Torres, Berta / Gonzalez-Cordón, Ana / Martinez, Esteban

The Journal of antimicrobial chemotherapy

2022 Volume 77, Issue 7, Page(s) 1974–1979

Abstract: Background: Tenofovir disoproxil fumarate, particularly when given with a ritonavir-boosted PI, reduces bone mineral density (BMD) and increases bone turnover markers (BTMs). Ritonavir-boosted atazanavir plus lamivudine is a feasible simplified option. ... ...

Abstract	Background: Tenofovir disoproxil fumarate, particularly when given with a ritonavir-boosted PI, reduces bone mineral density (BMD) and increases bone turnover markers (BTMs). Ritonavir-boosted atazanavir plus lamivudine is a feasible simplified option. We evaluated whether switching from a triple ritonavir-boosted PI plus tenofovir disoproxil fumarate to a two-drug regimen of lamivudine plus ritonavir-boosted atazanavir would improve BMD. Methods: Single-arm pilot study. Virologically suppressed patients on tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted PI with low BMD, without previous resistance mutations and/or virological failure to study drugs were switched to 100/300 mg of ritonavir-boosted atazanavir plus 300 mg of lamivudine once daily. The primary endpoint was BMD change by DXA at Week 48. Results: There were 31 patients, 4 (13%) female, and median age was 40 years. Seven participants (22.5%) had osteoporosis. At 48 weeks, mean (SD) changes in spine and hip BMD were +0.01 (0.03) (P = 0.0239) and +0.013 (0.03) g/cm2 (P = 0.0046), respectively. Mean (SD) T-score changes were +0.1 (0.23) (P = 0.0089) and +0.25 (0.76) (P = 0.0197), respectively. N-telopeptide and urine tenofovir disoproxil fumarate toxicity markers showed significant improvements. One participant withdrew from the study and two were lost to follow-up. There were no virological failures, or serious or grade 3-4 adverse events. Conclusions: Switching from a tenofovir disoproxil fumarate plus ritonavir-boosted PI triple therapy to a lamivudine plus ritonavir-boosted atazanavir two-drug regimen in virologically suppressed HIV-infected adults with low BMD was safe, increased low BMD and reduced plasma markers of bone turnover and urine markers of tenofovir disoproxil fumarate toxicity over 48 weeks.
MeSH term(s)	Adult ; Anti-HIV Agents/therapeutic use ; Atazanavir Sulfate/therapeutic use ; Bone Diseases, Metabolic/chemically induced ; Bone Diseases, Metabolic/prevention & control ; Drug Substitution ; Emtricitabine/therapeutic use ; Female ; HIV Infections/complications ; HIV Infections/drug therapy ; HIV Protease Inhibitors/therapeutic use ; Humans ; Lamivudine/therapeutic use ; Male ; Pilot Projects ; Ritonavir/adverse effects ; Ritonavir/therapeutic use ; Tenofovir/adverse effects ; Tenofovir/therapeutic use
Chemical Substances	Anti-HIV Agents ; HIV Protease Inhibitors ; Lamivudine (2T8Q726O95) ; Atazanavir Sulfate (4MT4VIE29P) ; Tenofovir (99YXE507IL) ; Emtricitabine (G70B4ETF4S) ; Ritonavir (O3J8G9O825)
Language	English
Publishing date	2022-05-05
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	191709-2
ISSN	1460-2091 ; 0305-7453
ISSN (online)	1460-2091
ISSN	0305-7453
DOI	10.1093/jac/dkac137
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1197: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 124: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Sclerosing Kaposi's sarcoma of the adrenal gland in an HIV-infected patient under antiretroviral therapy.

Castrejón, Natàlia / Nicolau, Carlos / González-Cordón, Ana / Archilla, Iván / Solé, Manel

Annals of diagnostic pathology

2018 Volume 38, Page(s) 123–125

MeSH term(s)	Adrenal Glands/diagnostic imaging ; Adrenal Glands/pathology ; Adrenal Glands/surgery ; Adrenal Glands/virology ; Adrenalectomy/methods ; Aftercare ; Antiretroviral Therapy, Highly Active/methods ; HIV Infections/complications ; HIV Infections/diagnosis ; HIV Infections/drug therapy ; HIV Infections/virology ; Herpesvirus 8, Human/isolation & purification ; Herpesvirus 8, Human/metabolism ; Humans ; Magnetic Resonance Imaging/methods ; Male ; Middle Aged ; Sarcoma, Kaposi/diagnostic imaging ; Sarcoma, Kaposi/pathology ; Sarcoma, Kaposi/surgery ; Sarcoma, Kaposi/ultrastructure ; Tomography, X-Ray Computed/methods ; Treatment Outcome
Language	English
Publishing date	2018-12-14
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	1440011-x
ISSN	1532-8198 ; 1092-9134
ISSN (online)	1532-8198
ISSN	1092-9134
DOI	10.1016/j.anndiagpath.2018.12.003
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5463: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito